Gerald Holtmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2493454/publications.pdf

Version: 2024-02-01

288 papers	15,322 citations	15466 65 h-index	22764 112 g-index
328 all docs	328 docs citations	328 times ranked	10018 citing authors

#	Article	IF	Citations
1	Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia. Digestive Diseases and Sciences, 2022, 67, 2299-2309.	1.1	16
2	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 128-140.	3.7	45
3	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet Gastroenterology and Hepatology, 2022, 7, 17-27.	3.7	44
4	Small intestinal bacterial overgrowth in inflammatory bowel disease. Indian Journal of Gastroenterology, 2022, 41, 23-29.	0.7	3
5	Duodenal Eosinophils and Mast Cells in Functional Dyspepsia: A Systematic Review and Meta-Analysis of Case-Control Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 2229-2242.e29.	2.4	22
6	Defects in NLRP6, autophagy and goblet cell homeostasis are associated with reduced duodenal CRH receptor 2 expression in patients with functional dyspepsia. Brain, Behavior, and Immunity, 2022, 101, 335-345.	2.0	12
7	Overlap of heartburn, functional dyspepsia, and irritable bowel syndrome in a population sample: Prevalence, temporal stability, and associated comorbidities. Neurogastroenterology and Motility, 2022, 34, e14349.	1.6	8
8	Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study. Digestive Diseases and Sciences, 2022, 67, 5593-5601.	1.1	13
9	Role of the duodenal microbiota in functional dyspepsia. Neurogastroenterology and Motility, 2022, 34, e14372.	1.6	10
10	Evidence-Based and Emerging Diet Recommendations for Small Bowel Disorders. American Journal of Gastroenterology, 2022, 117, 958-964.	0.2	3
11	Letter: nonâ€invasive transabdominal stimulation device for the treatment of chronic constipationâ€"proofâ€ofâ€principle study in adults. Alimentary Pharmacology and Therapeutics, 2022, 55, 1354-1356.	1.9	3
12	Current and Future Approaches for Diagnosing Small Intestinal Dysbiosis in Patients With Symptoms of Functional Dyspepsia. Frontiers in Neuroscience, 2022, 16, .	1.4	8
13	Zhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Trials, 2022, 23, .	0.7	1
14	Utilising lipid and, arginine and proline metabolism in blood plasma to differentiate the biochemical expression in functional dyspepsia (FD) and irritable bowel syndrome (IBS). Metabolomics, 2022, 18, .	1.4	6
15	Links between celiac disease and small intestinal bacterial overgrowth: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1844-1852.	1.4	5
16	Improving the Quality of Bowel Preparation: Rewarding Patients for Success or Intensive Patient Education?. Digestive Diseases, 2021, 39, 113-118.	0.8	5
17	Herbal medicines in functional dyspepsiaâ€"Untapped opportunities not without risks. Neurogastroenterology and Motility, 2021, 33, e14044.	1.6	11
18	Routine assessment of gastrointestinal symptom using a validated questionnaire in the clinical setting to assess the probability of organic or functional gastrointestinal diseases. Neurogastroenterology and Motility, 2021, 33, e14091.	1.6	2

#	Article	IF	Citations
19	Small Intestinal Bacterial Overgrowth in Functional Dyspepsia: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2021, 116, 935-942.	0.2	37
20	Epigastric symptom response to low FODMAP dietary advice compared with standard dietetic advice in individuals with functional dyspepsia. Neurogastroenterology and Motility, 2021, 33, e14148.	1.6	16
21	From trash to gold: gastrointestinal microbiome research in patients with functional gastrointestinal disorders. Journal of Investigative Medicine, 2021, 69, 793-795.	0.7	0
22	Dyspepsia: Treatment Options Directed to Specific Targets. Current Treatment Options in Gastroenterology, 2021, 19, 434-442.	0.3	0
23	Letter: budesonide for functional dyspepsia with duodenal eosinophiliaâ€"randomised, doubleâ€blind, placeboâ€controlled parallelâ€group trial. Alimentary Pharmacology and Therapeutics, 2021, 53, 1332-1333.	1.9	14
24	Patient Positioning Guidelines for Gastrointestinal Endoscopic Procedures. Gastroenterology Nursing, 2021, 44, 185-191.	0.2	4
25	Letter to the Editor: Oral Vancomycin Versus No Therapy for Pediatric Primary Sclerosing Cholangitis. Hepatology, 2021, 74, 1716-1717.	3.6	1
26	Clusters of community-dwelling individuals empirically derived from stool diaries correspond with clinically meaningful outcomes. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	1
27	Sleep disturbances in the irritable bowel syndrome and functional dyspepsia are independent of psychological distress: a populationâ€based study of 1322 Australians. Alimentary Pharmacology and Therapeutics, 2021, 54, 627-636.	1.9	9
28	Electroencephalographic evidence of unconscious and conscious attentional bias in people with functional gastrointestinal disorders: A pilot study. International Journal of Psychophysiology, 2021, 170, 30-42.	0.5	0
29	Draft Genome Sequence of Streptococcus salivarius AGIRA0003, Isolated from Functional Gastrointestinal Disorder Duodenal Tissue. Microbiology Resource Announcements, 2021, 10, e0075821.	0.3	2
30	Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis. Gut Microbes, 2021, 13, 1933313.	4.3	38
31	Is a Fundamental Design Change for Gastrointestinal Endoscopes Required?. Journal of Clinical Gastroenterology, 2021, 55, 21-24.	1.1	3
32	Antibiotic use but not gastrointestinal infection frequently precedes first diagnosis of functional gastrointestinal disorders. United European Gastroenterology Journal, 2021, 9, 1074-1080.	1.6	4
33	Physician Perceptions on the Use of Antibiotics and Probiotics in Adults: An International Survey in the Asia-Pacific Area. Frontiers in Cellular and Infection Microbiology, 2021, 11, 722700.	1.8	4
34	Autism-related dietary preferences mediate autism-gut microbiome associations. Cell, 2021, 184, 5916-5931.e17.	13.5	172
35	The role of mood state and emotion regulation in the discrepancy between gastrointestinal symptom burden recorded prospectively and via recall questionnaire. Neurogastroenterology and Motility, 2021, , e14304.	1.6	2
36	Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity. Gut, 2020, 69, 1719-1722.	6.1	24

#	Article	IF	Citations
37	Incidence and prevalence of selfâ€reported nonâ€coeliac wheat sensitivity and gluten avoidance in Australia. Medical Journal of Australia, 2020, 212, 126-131.	0.8	26
38	Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches. Digestive Diseases, 2020, 38, 269-279.	0.8	15
39	An Evidence-based Approach Towards Targeted Patient Education to Improve Bowel Preparation for Colonoscopy. Journal of Clinical Gastroenterology, 2020, 54, 707-713.	1.1	6
40	Mo1582 IS THERE AN ASSOCIATION BETWEEN IMPROVEMENT OF GI SYMPTOMS IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS AND ALTERATIONS OF CIRCULATING GUT HOMING T CELLS AND PRO-INFLAMMATORY CYTOKINES IN RESPONSE TO A 12 WEEK MULTIDISCIPLINARY INTERVENTION?. Gastroenterology, 2020, 158, S-904-S-905.	0.6	1
41	Su1204 VARIATIONS OF THE MUCOSA ASSOCIATED MICROBIOTA ALONG THE HUMAN GASTROINTESTINAL TRACT IN HEALTH AND INFLAMMATORY BOWEL DISEASE. Gastroenterology, 2020, 158, S-542.	0.6	1
42	A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review. Pharmacy (Basel, Switzerland), 2020, 8, 204.	0.6	9
43	Is there a causal link between psychological disorders and functional gastrointestinal disorders?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1047-1059.	1.4	26
44	Basics of meta-analysis. Indian Journal of Gastroenterology, 2020, 39, 503-513.	0.7	16
45	Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 155-167.	1.9	28
46	Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. American Journal of Gastroenterology, 2020, 115, 814-822.	0.2	48
47	Induction of Meal-related Symptoms as a Novel Mechanism of Action of the Duodenal-Jejunal Bypass Sleeve. Journal of Clinical Gastroenterology, 2020, 54, 528-535.	1.1	2
48	â€œIt ain't over â€¦ till it's over!â€• Riskâ€mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVIDâ€19 pandemic. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1117-1123.	1.4	12
49	Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. American Journal of Gastroenterology, 2020, 115, 1007-1018.	0.2	3
50	Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. American Journal of Gastroenterology, 2020, 115, 190-201.	0.2	102
51	Platelet activating factor receptor acts to limit colitisâ€induced liver inflammation. FASEB Journal, 2020, 34, 7718-7732.	0.2	14
52	Functional dyspepsia is associated with lower exercise levels: A populationâ€based study. United European Gastroenterology Journal, 2020, 8, 577-583.	1.6	13
53	Low ambient temperatures are associated with more rapid spread of COVID-19 in the early phase of the endemic. Environmental Research, 2020, 186, 109625.	3.7	38
54	Mo1544 IS SMALL INTESTINAL DYSBIOSIS (SIBO) RELATED TO IMPROVEMENT OF EPIGASTRIC PAIN, EARLY SATIETY AND POSTPRANDIAL PAIN IN RESPONSE TO ANTIMICROBIAL THERAPY WITH RIFAXIMIN IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS?. Gastroenterology, 2020, 158, S-889.	0.6	1

#	Article	IF	Citations
55	Link Between Celiac Disease and Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2019, 53, 514-522.	1.1	37
56	An in vitro and clinical dose-finding study of antifoaming effects of simethicone during colonoscopy. Indian Journal of Gastroenterology, 2019, 38, 268-272.	0.7	1
57	Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Seminars in Liver Disease, 2019, 39, 432-441.	1.8	52
58	The use of modelling studies to inform planning of health services: case study of rapidly increasing endoscopy services in Australia. BMC Health Services Research, 2019, 19, 608.	0.9	6
59	Population based study: atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress. Alimentary Pharmacology and Therapeutics, 2019, 49, 546-555.	1.9	62
60	The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complementary and Alternative Medicine, 2019, 19, 21.	3.7	153
61	Clinical Conditions Associated With Bacterial Overgrowth. , 2019, , 67-83.		7
62	Systematic review with metaâ€analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 624-635.	1.9	69
63	Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2019, 10, e00064.	1.3	33
64	Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Digestive Diseases and Sciences, 2019, 64, 480-486.	1.1	102
65	Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease. Clinical and Translational Gastroenterology, 2019, 10, e00068.	1.3	13
66	Immune Activation in Functional Gastrointestinal Disorders. Gastroenterology and Hepatology, 2019, 15, 539-548.	0.2	3
67	Transdiagnostic internet-delivered cognitive-behaviour therapy (CBT) for adults with functional gastrointestinal disorders (FGID): A feasibility open trial. Journal of Psychosomatic Research, 2018, 108, 61-69.	1.2	15
68	The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asiaâ€Pacific region â€•background and recommendations of a regional consensus meeting. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 57-69.	1.4	24
69	Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders. Wiener Medizinische Wochenschrift, 2018, 168, 89-98.	0.5	7
70	Gastroduodenal â€œDysbiosisâ€• a New Clinical Entity. Current Treatment Options in Gastroenterology, 2018, 16, 591-604.	0.3	22
71	A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?. Indian Journal of Gastroenterology, 2018, 37, 388-391.	0.7	6
72	Influence of cigarette smoking on the human duodenal mucosa-associated microbiota. Microbiome, 2018, 6, 150.	4.9	72

#	Article	IF	Citations
73	Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology?. Expert Review of Gastroenterology and Hepatology, 2018, 12, 633-635.	1.4	7
74	Influence of Simethicone Added to the Rinse Water during Colonoscopies on Polyp Detection Rates: Results of an Unintended Cohort Study. Digestion, 2018, 98, 217-221.	1.2	14
75	Opportunities of twin research in gastroenterology. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 325-326.	8.2	2
76	Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. American Journal of Clinical Nutrition, 2018, 107, 965-983.	2.2	408
77	Anti-TNFÎ± therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases. PLoS ONE, 2018, 13, e0193542.	1.1	42
78	Inconsistent symptom clusters for functional gastrointestinal disorders in Asia: is Rome burning?. Gut, 2018, 67, 1911-1915.	6.1	27
79	Seroreactivity to Microbial Antigens and Gutâ€Homing Immune Responses in Functional Dyspepsia Patients with Postprandial Distress Syndrome. FASEB Journal, 2018, 32, 613.3.	0.2	0
80	Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population. Clinical Gastroenterology and Hepatology, 2017, 15, 1014-1020.e4.	2.4	106
81	Dyspepsia and the microbiome: time to focus on the small intestine. Gut, 2017, 66, 1168-1169.	6.1	139
82	The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting. Digestive Diseases and Sciences, 2017, 62, 1913-1922.	1.1	45
83	Is There a Link Between H. Pylori and the Epidemiology of Crohnâ€™s Disease?. Digestive Diseases and Sciences, 2017, 62, 2472-2480.	1.1	14
84	Undiagnosed pancreatic exocrine insufficiency and chronic pancreatitis in functional GI disorder patients with diarrhea or abdominal pain. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1813-1817.	1.4	19
85	6. Konzepte der Arzneimitteltherapie. , 2017, , 229-272.		0
86	A randomized placeboâ€controlled trial on the effects of Menthacarin, a proprietary peppermintâ€and carawayâ€oilâ€preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterology and Motility, 2017, 29, e13132.	1.6	107
87	Life in the small intestine: the forgotten microbiome?. Microbiology Australia, 2017, 38, 116.	0.1	0
88	Functional dyspepsia. Nature Reviews Disease Primers, 2017, 3, 17081.	18.1	226
89	Gut Inflammation: More Than a Peripheral Annoyance. Digestive Diseases and Sciences, 2017, 62, 2205-2207.	1.1	3
90	Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Digestive Diseases, 2017, 35, 5-13.	0.8	115

#	Article	IF	Citations
91	Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. Seminars in Liver Disease, 2017, 37, 388-400.	1.8	55
92	Translating our microbiome into medicine. Medical Journal of Australia, 2017, 206, 287-288.	0.8	0
93	Anti-TNFA Treatment in Crohn's Disease Reduced GI Symptoms and Alters Motivational Circuitry in the Brain. Gastroenterology, 2017, 152, S924.	0.6	1
94	Irritable bowel syndrome, dyspepsia and other chronic disorders of gastrointestinal function. Medical Journal of Australia, 2016, 205, 303-304.	0.8	0
95	Liverâ€related mortality in countries of the developed world: an ecological study approach to explain the variability. Alimentary Pharmacology and Therapeutics, 2016, 44, 68-77.	1.9	9
96	Editorial: the burden of chronic liver disease â€“ an ecological method sees the wood for the trees. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 532-533.	1.9	0
97	Letter: investigating the intestinal mucosaâ€associated microbiota â€“ relevance and potential pitfalls. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 648-649.	1.9	0
98	Functional dyspepsia. Current Opinion in Gastroenterology, 2016, 32, 467-473.	1.0	59
99	Su1015 The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Use in the Clinical Setting. Gastroenterology, 2016, 150, S444.	0.6	1
100	Mo1629 Managing Functional Dyspepsia and IBS: Overlap Is Frequently Unrecognised in Clinical Practice, But Overlap Cases Are More Severely Impacted. Gastroenterology, 2016, 150, S735-S736.	0.6	1
101	Pathophysiology of irritable bowel syndrome. The Lancet Gastroenterology and Hepatology, 2016, 1, 133-146.	3.7	358
102	Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut, 2016, 65, 1402-1415.	6.1	144
103	Accuracy of polyp localization at colonoscopy. Endoscopy International Open, 2016, 04, E642-E646.	0.9	9
104	Characterisation of the gastrointestinal mucosaâ€associated microbiota: a novel technique to prevent crossâ€contamination during endoscopic procedures. Alimentary Pharmacology and Therapeutics, 2016, 43, 1186-1196.	1.9	69
105	Su1562 In Patients With Crohn's Disease Functional MRI Reveals an Alteration of Amygdala Function Induced by Anti-TNFa That Is Associated With Positive Self-attribution Biases and Reduced Symptom Response to a Standardised Nutrient Challenge. Gastroenterology, 2016, 150, S526-S527.	0.6	1
106	Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology, 2016, 16, 164-180.	0.5	71
107	Functional dyspepsia. Current Opinion in Gastroenterology, 2015, Publish Ahead of Print, 492-8.	1.0	18
108	Esophageal perforation, inflammatory mediastinitis and pseudoaneurysm of the thoracic aorta as potential complications of botulinum toxin injection for achalasia. Digestive Endoscopy, 2015, 27, 618-621.	1.3	13

#	Article	IF	Citations
109	Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. Journal of Gastroenterology, 2015, 50, 601-613.	2.3	57
110	Clinical triage for colonoscopy is useful in young women. Internal Medicine Journal, 2015, 45, 492-496.	0.5	7
111	Herbal Medicines for the Treatment of Functional and InflammatoryÂBowel Disorders. Clinical Gastroenterology and Hepatology, 2015, 13, 422-432.	2.4	32
112	Non-physician endoscopists: A systematic review. World Journal of Gastroenterology, 2015, 21, 5056.	1.4	20
113	Funktionelle Dyspepsie (funktionelle Magenbeschwerden). , 2015, , 1-4.		0
114	Cost and time savings from a rapid access model of care using transient elastography to screen and triage patients with chronic Hepatitis C infection. Journal of Medical Economics, 2014, 17, 159-165.	1.0	5
115	Review article: associations betweenHelicobacter pyloriand obesity - an ecological study. Alimentary Pharmacology and Therapeutics, 2014, 40, 24-31.	1.9	89
116	Complicated and Uncomplicated Peptic Ulcer Disease: Altered Symptom Response to a Nutrient Challenge Linked to Gastric Motor Dysfunction. Digestion, 2014, 89, 239-246.	1.2	9
117	Letter: inverse correlation betweenHelicobacter pyloriand obesity - a conclusion too early? Authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 1120-1120.	1.9	0
118	Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients. Brain, Behavior, and Immunity, 2014, 42, 191-203.	2.0	44
119	The stomachâ€"brain axis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 967-979.	1.0	40
120	Host immune response determines visceral hyperalgesia in a rat model of post-inflammatory irritable bowel syndrome. Journal of Gastroenterology, 2013, 48, 1119-1127.	2.3	14
121	Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes. Gut, 2013, 62, 1456-1465.	6.1	172
122	Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting. World Journal of Gastroenterology, 2013, 19, 2514.	1.4	8
123	A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2012, 6, 302-310.	0.6	99
124	An Integrated Model of Care for Inflammatory Bowel Disease Sufferers in Australia: Development and the Effects of Its Implementation. Inflammatory Bowel Diseases, 2012, 18, 1573-1581.	0.9	35
125	Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelinesâ€based audit. Internal Medicine Journal, 2012, 42, e84-8.	0.5	5
126	Itopride in the Treatment of Functional Dyspepsia in Chinese Patients. Clinical Drug Investigation, 2011, 31, 865-875.	1.1	17

#	Article	IF	Citations
127	Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 916-923.	1.4	72
128	Is there an association between hospital accreditation and patient satisfaction with hospital care? A survey of 37 000 patients treated by 73 hospitals. International Journal for Quality in Health Care, 2011, 23, 278-283.	0.9	89
129	Stress causes flares of IBDâ€"how much evidence is enough?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 13-14.	8.2	9
130	Improvement of Non-Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal Symptoms during Proton Pump Inhibitor Treatment: Are G-Protein Î²3 Subunit Genotype, Helicobacter pylori Status, and Environmental Factors Response Modifiers?. Digestion, 2011, 84, 289-298.	1.2	7
131	Small Bowel Homing T Cells Are Associated With Symptoms and Delayed Gastric Emptying in Functional Dyspepsia. American Journal of Gastroenterology, 2011, 106, 1089-1098.	0.2	149
132	Itopride in the Treatment of Functional Dyspepsia in Chinese Patients. Clinical Drug Investigation, 2011, , 1.	1.1	2
133	Recombinant human erythropoietin counteracts cisplatin-induced visceral hyperalgesia. Neuroscience Bulletin, 2010, 26, 282-288.	1.5	3
134	Challenging the holy grail of hospital accreditation: A cross sectional study of inpatient satisfaction in the field of cardiology. BMC Health Services Research, 2010, 10, 120.	0.9	40
135	Onset of relief of symptoms of gastroesophageal reflux disease: Post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. Clinical Therapeutics, 2010, 32, 678-690.	1.1	12
136	Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia?. Neurogastroenterology and Motility, 2010, 22, 262-e79.	1.6	51
137	Association between clinical manifestations of complicated and uncomplicated peptic ulcer and visceral sensory dysfunction. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1162-1169.	1.4	14
138	Adverse clinical phenotype in inflammatory bowel disease: A cross sectional study identifying factors potentially amenable to change. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1250-1258.	1.4	33
139	Unâ€promoted issues in inflammatory bowel disease: opportunities to optimize care. Internal Medicine Journal, 2010, 40, 173-182.	0.5	44
140	Are All Symptoms in Patients in IBD Due to Occult Inflammation?. American Journal of Gastroenterology, 2010, 105, 2703.	0.2	1
141	The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: A single metropolitan Australian center experience. Journal of Crohn's and Colitis, 2010, 4, 413-421.	0.6	32
142	Kolondivertikulose, Divertikulitis und Divertikelblutung. DoctorConsult - the Journal Wissen Fur Klinik Und Praxis, 2010, 1, e151-e155.	0.0	0
143	Management of Reflux Symptoms with Over-the-Counter Proton Pump Inhibitors: Issues and Proposed Guidelines. Digestion, 2009, 80, 226-234.	1.2	26
144	TRPV1-expressing sensory fibres and IBS: links with immune function. Gut, 2009, 58, 465-466.	6.1	37

#	Article	IF	Citations
145	Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders â€“ an evaluation study. BMC Health Services Research, 2009, 9, 17.	0.9	18
146	Recurrent Symptoms after Fundoplication with a Negative pH Studyâ€"Recurrent Reflux or Functional Heartburn?. Journal of Gastrointestinal Surgery, 2009, 13, 54-60.	0.9	19
147	International validation of a healthâ€related quality of life questionnaire in patients with erosive gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2009, 29, 615-625.	1.9	24
148	Clinical trial: the treatment of gastroâ€oesophageal reflux disease in primary care â€“ prospective randomized comparison of rabeprazole 20â€ƒmg with esomeprazole 20 and 40â€ƒmg. Alimentary Pharmacology and Therapeutics, 2009, 29, 967-978.	1.9	22
149	Psychogastroenterology: a call for psychological input in Australian gastroenterology clinics. Internal Medicine Journal, 2009, 39, 127-130.	0.5	14
150	G protein-coupled receptor kinase 6 controls post-inflammatory visceral hyperalgesia. Brain, Behavior, and Immunity, 2009, 23, 18-26.	2.0	21
151	The Ion Channel TRPA1 Is Required for Normal Mechanosensation and Is Modulated by Algesic Stimuli. Gastroenterology, 2009, 137, 2084-2095.e3.	0.6	232
152	P172 - In what proportion of IBD patients coming to resection surgery was there an opportunity to optimise preoperative care? A one year audit of a tertiary referral hospital. Journal of Crohn's and Colitis, 2009, 3, S79.	0.6	2
153	Serotoninergic and non-serotoninergic effects of two tricyclic antidepressants on visceral nociception in a rat model. Scandinavian Journal of Gastroenterology, 2009, 44, 680-686.	0.6	2
154	Relationship Between Symptoms and Dietary Patterns in Patients With Functional Dyspepsia. Clinical Gastroenterology and Hepatology, 2009, 7, 317-322.	2.4	102
155	Do We Know What Patients Want? The Doctor-Patient Communication Gap in Functional Gastrointestinal Disorders. Clinical Gastroenterology and Hepatology, 2009, 7, 1252-1254.e2.	2.4	38
156	Does doctorsÊ¼ knowledge of inflammatory bowel disease patientsÊ¼ psychological status affect patientsÊ¼ clinical outcomes: a pilot randomized controlled trial. European Journal of Gastroenterology and Hepatology, 2009, 21, 484-485.	0.8	4
157	Asiaâ€Pacific consensus on the management of gastroesophageal reflux disease: Update. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 8-22.	1.4	156
158	New algorithm for the treatment of gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2008, 27, 249-256.	1.9	87
159	Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: An observational cohort prospective study. BioPsychoSocial Medicine, 2008, 2, 11.	0.9	44
160	Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1137-1143.	1.4	43
161	Impairment of healthâ€related quality of life in functional dyspepsia and chronic liver disease: the influence of depression and anxiety. Alimentary Pharmacology and Therapeutics, 2008, 27, 561-571.	1.9	44
162	Systematic review: healthâ€related quality of life (HRQOL) questionnaires in gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2008, 27, 1053-1070.	1.9	33

#	Article	IF	Citations
163	The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 475-483.	1.9	54
164	Failed Therapy and Directions for the Future in Dyspepsia. Digestive Diseases, 2008, 26, 218-224.	0.8	23
165	530 Complicated and Uncomplicated Peptic Ulcer Disease: the Altered Symptom Response to the Nutrient Challenge Is Linked to Gastric Motor Function. Gastroenterology, 2008, 134, A-75.	0.6	1
166	Selective Role for TRPV4 Ion Channels in Visceral Sensory Pathways. Gastroenterology, 2008, 134, 2059-2069.	0.6	228
167	Psychological problems in gastroenterology outpatients: A South Australian experience. Psychological co-morbidity in IBD, IBS and hepatitis C. Clinical Practice and Epidemiology in Mental Health, 2008, 4, 15.	0.6	43
168	Non-Erosive Reflux Disease â€“ Defining the Entity and Delineating the Management. Digestion, 2008, 78, 1-5.	1.2	19
169	Functional Dyspepsia Is Associated With a Greater Symptomatic Response to Fat But Not Carbohydrate, Increased Fasting and Postprandial CCK, and Diminished PYY. American Journal of Gastroenterology, 2008, 103, 2613-2623.	0.2	124
170	Mechanisms of Disease: genetics of functional gastrointestinal disordersâ€"searching the genes that matter. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 102-110.	1.7	38
171	On-demand Treatment of Acute Heartburn With the Antacid Hydrotalcite Compared With Famotidine and Placebo. Journal of Clinical Gastroenterology, 2007, 41, 564-570.	1.1	12
172	GERD Evaluation. Journal of Clinical Gastroenterology, 2007, 41, 237-241.	1.1	12
173	GERD. Journal of Clinical Gastroenterology, 2007, 41, S204-S208.	1.1	0
174	Increased visceral sensitivity to capsaicin after DSS-induced colitis in mice: spinal cord c-Fos expression and behavior. American Journal of Physiology - Renal Physiology, 2007, 293, G749-G757.	1.6	80
175	Effects of IberogastÂ® on Proximal Gastric Volume, Antropyloroduodenal Motility and Gastric Emptying in Healthy Men. American Journal of Gastroenterology, 2007, 102, 1276-1283.	0.2	104
176	A genetic association study of 5-HTT LPR and GN?3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterology and Motility, 2007, 19, 465-470.	1.6	71
177	Immune Activation in Patients With Irritable Bowel Syndrome. Gastroenterology, 2007, 132, 913-920.	0.6	561
178	Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2007, 13, 225-234.	0.9	146
179	Psychological stress and the severity of post-inflammatory visceral hyperalgesia. European Journal of Pain, 2007, 11, 216-222.	1.4	28
180	"It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterology, 2007, 7, 38.	0.8	36

#	Article	IF	Citations
181	Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy?. Alimentary Pharmacology and Therapeutics, 2007, 25, 973-986.	1.9	82
182	Neuroendocrine and blood pressure responses to rectal distensions in individuals with high and low visceral pain sensitivity. Psychoneuroendocrinology, 2007, 32, 580-585.	1.3	11
183	Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission. Journal of Neuroimmunology, 2007, 182, 195-203.	1.1	22
184	A combination of peppermint oil and caraway oil attenuates the post-inflammatory visceral hyperalgesia in a rat model. Scandinavian Journal of Gastroenterology, 2006, 41, 155-160.	0.6	37
185	Public Speaking Stress-Induced Neuroendocrine Responses and Circulating Immune Cell Redistribution in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 2300-2307.	0.2	51
186	Functional Gastroduodenal Disorders. Gastroenterology, 2006, 130, 1466-1479.	0.6	1,740
187	Visceral pain and public speaking stress: Neuroendocrine and immune cell responses in healthy subjects. Brain, Behavior, and Immunity, 2006, 20, 49-56.	2.0	26
188	Hypothesis Driven Research and Molecular Mechanisms in Functional Dyspepsia: The Beginning of a Beautiful Friendship in Research and Practice?. American Journal of Gastroenterology, 2006, 101, 593-595.	0.2	33
189	Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Pain, 2006, 123, 179-186.	2.0	85
190	Prevalence of Unexplained Upper Abdominal Symptoms in Patients with Migraine. Cephalalgia, 2006, 26, 506-510.	1.8	54
191	Review article: From gastrin to gastro-oesophageal reflux disease - a century of acid suppression. Alimentary Pharmacology and Therapeutics, 2006, 23, 683-690.	1.9	25
192	Ablation of connexin43 in smooth muscle cells of the mouse intestine: functional insights into physiology and morphology. Cell and Tissue Research, 2006, 327, 333-342.	1.5	18
193	Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5. Phytomedicine, 2006, 13, 114-121.	2.3	72
194	Antidepressants and inflammatory bowel disease: a systematic review. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 24.	0.6	103
195	A Placebo-Controlled Trial of Itopride in Functional Dyspepsia. New England Journal of Medicine, 2006, 354, 832-840.	13.9	228
196	Susceptibility genes and functional gastrointestinal disorders. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1792-1793.	1.4	2
197	Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model. Neurogastroenterology and Motility, 2005, 17, 410-414.	1.6	35
198	Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2005, 21, 11-20.	1.9	33

#	Article	IF	Citations
199	Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2005, 22, 357-363.	1.9	88
200	MR Colonography in Patients with Incomplete Conventional Colonoscopy. Radiology, 2005, 234, 452-459.	3.6	64
201	Funktionelle Dyspepsie und Reizdarmsyndrom. , 2005, , 435-447.		1
202	Understanding GERD symptoms in the clinical setting. Drugs of Today, 2005, 41 Suppl B, 13-7.	0.7	2
203	Treatment of Functional Dyspepsia with a Herbal Preparation. Digestion, 2004, 69, 45-52.	1.2	95
204	Symptom patterns in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters. Gut, 2004, 53, 1445-1451.	6.1	65
205	Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Alimentary Pharmacology and Therapeutics, 2004, 19, 271-279.	1.9	175
206	Review article: the patient with gastro-oesophageal reflux disease - lifestyle advice and medication. Alimentary Pharmacology and Therapeutics, 2004, 20, 24-27.	1.9	32
207	Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2004, 20, 47-56.	1.9	38
208	Management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2004, 19, 66-70.	1.9	9
209	Long-Term Effects of Transient Chemically Induced Colitis on the Visceromotor Response to Mechanical Colorectal Distension. Digestive Diseases and Sciences, 2004, 49, 96-101.	1.1	60
210	Clinical Presentation and Personality Factors Are Predictors of the Response to Treatment in Patients with Functional Dyspepsia: A Randomized, Double-Blind Placebo-Controlled Crossover Study. Digestive Diseases and Sciences, 2004, 49, 672-679.	1.1	41
211	Heartburn in primary care: problems below the surface. Journal of Gastroenterology, 2004, 39, 1027-1034.	2.3	8
212	Molecular basis of functional gastrointestinal disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 633-640.	1.0	17
213	Intraoperative cholangioscopy in the management of biliary adenomas. Journal of Surgical Oncology, 2004, 85, 91-92.	0.8	3
214	Real-time high-resolution MRI for the assessment of gastric motility: Pre- and postpharmacological stimuli. Journal of Magnetic Resonance Imaging, 2004, 19, 453-458.	1.9	35
215	IBS: A syndrome or many diseases?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 91-97.	1.0	10
216	Real time high resolution magnetic resonance imaging for the assessment of gastric motility disorders. Gut, 2004, 53, 1256-1261.	6.1	108

#	Article	IF	Citations
217	Determinants of health-related quality of life in patients with chronic liver diseases. Clinical Gastroenterology and Hepatology, 2004, 2, 157-163.	2.4	95
218	G-protein Î²3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia 1 â˜†. Gastroenterology, 2004, 126, 971-979.	0.6	225
219	Are There Alterations of Neuroendocrine and Cellular Immune Responses to Nutrients in Women with Irritable Bowel Syndrome?. American Journal of Gastroenterology, 2004, 99, 703-710.	0.2	62
220	Papillomatosis Confined to the Distal Biliary Tract ? A Rare Cause of Obstructive Jaundice: Report of a Case. Surgery Today, 2003, 33, 781-784.	0.7	10
221	Effects of a fixed combination of peppermint oil and caraway oil on symptoms and quality of life in patients suffering from functional dyspepsia. Phytomedicine, 2003, 10, 56-57.	2.3	28
222	Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2003, 18, 569-580.	1.9	73
223	Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Alimentary Pharmacology and Therapeutics, 2003, 18, 1099-1105.	1.9	112
224	Serum ferritin and survival of renal transplant recipients: a prospective 10-year cohort study. Transplant International, 2003, 16, 642-647.	0.8	8
225	Genetics, H. pylori and the development of functional gastrointestinal disorders: A twin study. Gastroenterology, 2003, 124, A391.	0.6	2
226	Persistently Altered Visceral Perception after Resection of an Esophageal Granular Cell Myoblastoma: A Therapeutic Concept Revisited. Zeitschrift Fur Gastroenterologie, 2003, 41, 917-920.	0.2	0
227	Time-Resolved Three-Dimensional MR Imaging of Gastric Emptying Modified by IV Administration of Erythromycin. American Journal of Roentgenology, 2003, 180, 1305-1310.	1.0	23
228	GERD 2003 â€“ A Consensus on the Way Ahead. Digestion, 2003, 67, 111-117.	1.2	41
229	MR Colonography with Barium-based Fecal Tagging: Initial Clinical Experience. Radiology, 2002, 223, 248-254.	3.6	127
230	Effect of transient chemically induced colitis on the visceromotor response to mechanical colorectal distension. European Journal of Gastroenterology and Hepatology, 2002, 14, 1067-1072.	0.8	27
231	(Post) inflammatory visceral hyperalgesia: Don't we believe what we don't see?. Gastroenterology, 2002, 122, 823-825.	0.6	1
232	Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?. Gastroenterology, 2002, 123, 1451-1458.	0.6	42
233	Capsaicin-Sensitive Nerve Fibres Induce Epithelial Cell Proliferation, Inflammatory Cell Immigration and Transforming Growth Factor-alpha Expression in the Rat Colonic Mucosa In Vivo. Scandinavian Journal of Gastroenterology, 2002, 37, 414-422.	0.6	26
234	A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2002, 16, 479-485.	1.9	71

#	Article	IF	Citations
235	A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2002, 16, 1641-1648.	1.9	81
236	Effects of a fixed peppermint oil caraway oil combination (PCC) on symptoms and quality of life in functional dyspepsia. Gastroenterology, 2001, 120, A237.	0.6	1
237	Epidemiological Trends of Functional Gastrointestinal Disorders. Digestive Diseases, 2001, 19, 189-194.	0.8	20
238	Epithelial cell-derived components induce transforming growth factor-Î± mRNA expression and epithelial cell proliferation in vitro. European Journal of Gastroenterology and Hepatology, 2001, 13, 1333-1340.	0.8	7
239	The management of irritable bowel syndrome: a European, primary and secondary care collaboration. European Journal of Gastroenterology and Hepatology, 2001, 13, 933-939.	0.8	17
240	Diurnal variation of abdominal motor responses to colorectal distension and plasma cortisol levels in rats. Neurogastroenterology and Motility, 2001, 13, 585-589.	1.6	20
241	H. pylori and functional dyspepsia: increased serum antibodies as an independent risk factor?. Digestive Diseases and Sciences, 2001, 46, 1550-1557.	1.1	12
242	MR Colonography Without Colonic Cleansing. American Journal of Roentgenology, 2001, 177, 823-827.	1.0	86
243	Effects of a fixed peppermint oil caraway oil combination (PCC) on symptoms and quality of life in functional dyspepsia. Gastroenterology, 2001, 120, A237-A237.	0.6	3
244	Opiodergic antinociceptive pathways modulate gastric mechanosensory function in healthy subjects. Gastroenterology, 2001, 120, A81-A81.	0.6	1
245	Reflux disease: the disorder of the third millennium. European Journal of Gastroenterology and Hepatology, 2001, 13 Suppl 1, S5-11.	0.8	25
246	Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. American Journal of Gastroenterology, 2000, 95, 1439-1447.	0.2	101
247	Differences in gastric mechanosensory function after repeated ramp distensions in non-consulters with dyspepsia and healthy controls. Gut, 2000, 47, 332-336.	6.1	75
248	Differential involvement of spinal NMDA, CGRP and NK1 receptors in responses to phasic vs. tonic colorectal distension. Gastroenterology, 2000, 118, A380.	0.6	1
249	Diurnal variation of abdominal motor responses to colorectal distension in a rat model. Gastroenterology, 2000, 118, A135.	0.6	1
250	Prokinetics in Patients with Gastroparesis: A Systematic Analysis. Digestion, 1999, 60, 422-427.	1.2	199
251	Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Alimentary Pharmacology and Therapeutics, 1999, 13, 225-235.	1.9	197
252	Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Alimentary Pharmacology and Therapeutics, 1999, 13, 1459-1465.	1.9	43

#	Article	IF	Citations
253	Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Alimentary Pharmacology and Therapeutics, 1999, 13, 1419-1427.	1.9	122
254	Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology, 1999, 117, 11-16.	0.6	201
255	1 Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. Bailliere's Clinical Gastroenterology, 1998, 12, 417-433.	0.9	41
256	Involvement of chloride channels in the receptormediated activation of longitudinal colonic muscle. Neurogastroenterology and Motility, 1998, 10, 489-498.	1.6	3
257	AGA technical review: Evaluation of dyspepsia. Gastroenterology, 1998, 114, 582-595.	0.6	378
258	Altered vagal and intestinal mechanosensory function in chronic unexplained dyspepsia. Gut, 1998, 42, 501-506.	6.1	116
259	Nonischemic Chest Pain Induced by Coronary Interventions. Circulation, 1998, 98, 2656-2658.	1.6	46
260	Antibody Response to Specific H. Pylori Antigens in Functional Dyspepsia, Duodenal Ulcer Disease, and Health. American Journal of Gastroenterology, 1998, 93, 1222-1227.	0.2	39
261	Altered postprandial motility in chronic pancreatitis: Role of malabsorption. Gastroenterology, 1997, 112, 1624-1634.	0.6	90
262	Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. American Journal of Physiology - Renal Physiology, 1997, 273, G553-G558.	1.6	23
263	Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis?. American Journal of Gastroenterology, 1997, 92, 954-9.	0.2	84
264	Proton-pump inhibitors or H2-receptor antagonists for Helicobacter pylori eradicationâ€"a meta-analysis. Lancet, The, 1996, 347, 763.	6.3	20
265	A prospective randomized experimental evaluation of three-dimensional imaging in laparoscopy. Gastrointestinal Endoscopy, 1996, 44, 262-267.	0.5	60
266	Association betweenH. pylori, duodenal mechanosensory thresholds, and small intestinal motility in chronic unexplained dyspepsia. Digestive Diseases and Sciences, 1996, 41, 1285-1291.	1.1	52
267	Nutrients and cyclical interdigestive pancreatic enzyme secretion in humans.. Gut, 1996, 38, 920-924.	6.1	12
268	Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia. American Journal of Gastroenterology, 1996, 91, 485-91.	0.2	59
269	Perception of gastric distension. Digestive Diseases and Sciences, 1995, 40, 2673-2677.	1.1	19
270	Gastrointestinal sensory function in functional dyspepsia. Gastroenterology, 1995, 109, 331.	0.6	12

#	Article	IF	Citations
271	Report of a Case With Giant Condyloma (Buschke-Lowenstein Tumor) Localized in the Bladder. Journal of Urology, 1995, 153, 1222-1224.	0.2	23
272	Gastrointestinal problems in airline crew members. Zeitschrift Fur Gastroenterologie, 1995, 33, 513-6.	0.2	5
273	Pancreatic enzymes in chronic pancreatitis. International Journal of Gastrointestinal Cancer, 1994, 15, 1-11.	0.4	49
274	Dyspepsia in healthy blood donors. Digestive Diseases and Sciences, 1994, 39, 1090-1098.	1.1	111
275	Dyspepsia in consulters and non-consulters. European Journal of Gastroenterology and Hepatology, 1994, 6, 917-924.	0.8	89
276	Effects of neurokinins on human colonic motility. Neurogastroenterology and Motility, 1994, 6, 119-127.	1.6	9
277	Functional Dyspepsia. Drugs, 1993, 45, 918-930.	4.9	66
278	Does long-term maintenance therapy with ranitidine affect the natural course of duodenal ulcer disease?. European Journal of Gastroenterology and Hepatology, 1993, 5, 311-318.	0.8	4
279	Influence of Stress on the Healing and Relapse of Duodenal Ulcers: A Prospective, Multicenter Trial of 2109 Patients with Recurrent Duodenal Ulceration Treated with Ranitidine. Scandinavian Journal of Gastroenterology, 1992, 27, 917-923.	0.6	39
280	Stress and gastrointestinal motility in animals: a review of the literature. Neurogastroenterology and Motility, 1992, 4, 83-90.	1.6	30
281	Stress and Gastrointestinal Motility in Humans: A Review of the Literature. Neurogastroenterology and Motility, 1991, 3, 245-254.	1.6	29
282	Mental stress and gastric acid secretion. Digestive Diseases and Sciences, 1990, 35, 998-1007.	1.1	49
283	Telenzepine, a New M1-Receptor Antagonist, Is a More Potent Inhibitor of Pentagastrin-Stimulated Gastric Acid Output Than Pirenzepine in Dogs. Scandinavian Journal of Gastroenterology, 1990, 25, 293-297.	0.6	5
284	Telenzepine, a new M1-receptor antagonist, is a more potent inhibitor of pentagastrin-stimulated gastric acid output than pirenzepine in dogs. Scandinavian Journal of Gastroenterology, 1990, 25, 293-7.	0.6	0
285	Differential effects of acute mental stress on interdigestive secretion of gastric acid, pancreatic enzymes, and gastroduodenal motility. Digestive Diseases and Sciences, 1989, 34, 1701-1707.	1.1	53
286	The effect of a new synthetic cholinergic compound (Aclatonium Napadisilate) on interdigestive motility and pancreatic function in humans. International Journal of Gastrointestinal Cancer, 1989, 5, 273-279.	0.4	1
287	Histamine H2 receptor antagonists and blood alcohol levels. Digestive Diseases and Sciences, 1988, 33, 767-768.	1.1	11
288	Approach to the Patient with Dyspepsia and Related Functional Gastrointestinal Complaints. , 0, , 38-61.		2